Track topics on Twitter Track topics that are important to you
Novartis International AG / Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basel, May 17, 2018 - Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 in Chicago; and the 23rd Annual Congress of the European Hematology Association (EHA), scheduled for June 14-17 in Stockholm. With studies highlighting more than 25 compounds investigated in a range of disease areas including breast, renal cell and lung cancers, leukemias and other blood disorders, and myeloproliferative neoplasms (MPNs), the 84 abstracts that are part of the ASCO and EHA scientific programs illustrate the breadth and depth of Novartis' work in oncology.
"Novartis is improving the lives of people with cancer through a relentless commitment to scientific innovation," said Liz Barrett, CEO, Novartis Oncology. "Whether examining investigational treatment combinations, investigating treatment options that may redefine treatment goals of diseases like CML, or demonstrating the value of our therapies through real-world studies, Novartis continues to push boundaries as we reimagine cancer."
Novartis data at the 2018 ASCO Annual Meeting will highlight the following:
New data evaluating Kisqali® (ribociclib)* in broad range of patients with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer and additional update on investigational treatment, BYL719 (alpelisib):
Data evaluating real-world effectiveness and safety outcomes of first-line Votrient® (pazopanib) in patients with advanced renal cell carcinoma (RCC):
New analyses of ENESTop and ENESTfreedom evaluating Treatment-free Remission (TFR) at 144-week follow-up after Tasigna® (nilotinib) treatment discontinuation in eligible adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP):
Additional data presented at ASCO include:
Sandoz, a Novartis division and the pioneer and global leader in biosimilars will present data for the company's filgrastim biosimilar:
Advanced Accelerator Applications, a Novartis company and leader in nuclear medicine theragnostics, will present an update on outcomes from the NETTER-1 study evaluating Lutathera® (lutetium Lu 177 dotatate) in patients with progressive midgut neuroendocrine tumors:
Novartis data at the 2018 EHA Annual Congress will highlight the following:
Updates on outcomes with Kymriah® (tisagenlecleucel) in adult relapsed or refractory (r/r) patients with diffuse large b-cell lymphoma (DLBCL) and patient-reported quality of life in pediatric and young adult patients with r/r B-cell acute lymphoblastic leukemia (B-ALL)**:
New data evaluating Jakavi® (ruxolitinib)*** for patients with myelofibrosis, including those with early stage disease, and patients with polycythemia vera who are resistant to or intolerant of hydroxyurea:
Further analyses of ENESTop and ENESTfreedom evaluating TFR at 144-week follow-up after Tasigna® (nilotinib) treatment discontinuation in eligible adult patients with Ph+ CML-CP:
Safety analysis of the SUSTAIN study evaluating crizanlizumab in patients with sickle cell disease:
New data evaluating Revolade® (eltrombopag) in patients with either persistent or chronic immune thrombocytopenia (ITP):
Interim results from the ITP World Impact Survey (I-WISh) about the burden of disease and impact of ITP on patient quality of life and productivity:
Throughout the 2018 ASCO Annual Meeting and EHA Annual Congress, Novartis will host dedicated content on https://www.novartis.com/our-focus/cancer that will feature unique insights and perspectives on emerging areas of cancer care and research.
Approved indications for products vary by country and not all indications are available in every country. The product safety and efficacy profiles have not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that compounds will become commercially available with additional indications.
For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/our-company/global-product-portfolio.
For Lutathera® full prescribing information, including approved indications and important safety, please visit https://lutathera.com.
Alpelisib (BYL719), LAG525, spartalizumab (PDR001), LXH254 and crizanlizumab (SEG101) are investigational compounds. Efficacy and safety have not been established. There is no guarantee these compounds will become commercially available.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 124,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact firstname.lastname@example.org
* Kisqali was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals.
** Novartis and the University of Pennsylvania's Perelman School of Medicine (Penn) have a global collaboration to research, develop and commercialize chimeric antigen receptor T cell (CAR-T) therapies for the investigational treatment of cancers.
*** Jakavi is a registered trademark of Novartis AG in countries outside the United States. Jakafi is a registered trademark of Incyte Corporation. Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the United States.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
| Eric Althoff|
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
| Mary Curtin Creaser|
Novartis Oncology Communications
+1 862 778 2550 (direct)
+1 862 345 4102 (mobile)
Sandoz Global Biopharma Communications
+1 973 714 8043 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Richard Pulik||+1 212 830 2448|
|Pierre-Michel Bringer||+41 61 324 1065||Cory Twining||+1 212 830 2417|
|Thomas Hungerbuehler||+41 61 324 8425|
|Isabella Zinck||+41 61 324 7188|
--- End of Message ---
Novartis International AG
P.O. Box Basel Switzerland
WKN: 904278;ISIN: CH0012005267;
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...